Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Signs Collaboration Agreement with Sysmex Inostics

Published: Sunday, June 01, 2014
Last Updated: Wednesday, June 04, 2014
Bookmark and Share
Collaboration for the development and commercialization of a blood-based RAS biomarker test.

Merck announced today that the company has signed an agreement to collaborate with Sysmex Inostics GmbH, Hamburg, Germany, for the development and commercialization of a blood-based RAS biomarker test for patients with metastatic colorectal cancer (mCRC). This global agreement was formally signed at a ceremony coinciding with the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, U.S.

Blood-based biomarker testing is a faster and easier approach for determining the mutation status of tumors as it requires a small blood sample rather than a tissue biopsy procedure.1 The test has the potential to provide mutation status results within days, which in turn can help guide treatment decisions.1 In addition, it may become the method of choice where a tissue biopsy is difficult to obtain, for example in patients whose physical condition does not allow for a surgical procedure.

“We are delighted to announce our strategic partnership with Sysmex Inostics,” said Belén Garijo, President and CEO of Merck Serono. “As a company, we have embraced the principles of personalized medicine and predictive biomarkers. This collaboration reflects our commitment to leveraging our expertise in personalized medicine and predictive biomarkers in order to enhance Erbitux’s value proposition for patients, physicians and payers.”

“We are looking forward to this important collaboration with Merck Serono and to bringing our innovative technology to mCRC patients,” said Fernando Andreu, CEO of Sysmex Inostics. “Together with our non-invasive, blood-based diagnostics and Merck’s expertise in personalized medicine, we will open up new possibilities to advance biomarker testing in mCRC. This collaboration is another major step in enhancing the clinical value of Sysmex Inostics’s OncoBEAM tests and exemplifies Sysmex’s overall strategy to bring sensitive blood-based testing to the Oncology field.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test
Companies to develop and commercialize of a RAS kit for patients with metastatic colorectal cancer (mCRC).
Wednesday, June 04, 2014
Apitope and Merck Serono Announce Licensing Agreement on Peptide Therapeutics for Multiple Sclerosis
Under this agreement, Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467.
Wednesday, January 14, 2009
New President of Merck Research Laboratories Named

Tuesday, December 03, 2002
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
RNA Suppresses Inflammation
Researchers identify a long noncoding RNA that regulates innate immunity.
Competition to Decipher RNA-Cancer Link
DREAM challenge aims to find the best algorithms for detecting abnormal RNA molecules in cancer cells.
Red Hair Gene Increases Cancer Mutations
Red hair gene variant drives up skin cancer mutations equivalent to that expected from 21 years of sun exposure.
Type 2 Diabetes Genetics Revealed
The largest study of its kind into type 2 diabetes has produced the most detailed picture to date of the genetics underlying the condition.
Blood Cancer Could be Prevented Before it Develops
New research suggests myeloma could be prevented before it develops out of symptomless condition in bone marrow.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!